Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy

Hai-bin YU; Li-na MA; Ya-li LIU; Wei HUA; Zhi-min HE; Jun-feng LU; Xin-yue CHEN.
Chinese Journal of Hepatology ; (12): 895-898, 2013.
Artículo en Zh | WPRIM | ID: wpr-252303

Documentos relacionados

  1. [Changes in lymphocyte surface expression of CD8 and CD38 molecules in peripheral blood of inactive HBsAg carriers following pegylated interferon a-2a therapy].
  2. Indicaciones y Complicaciones del Implante de Marcapasos Endocárdico Percutáneo Definitivo en Paciente del Hospital Militar Central de El Salvador en el Periodo de Enero 2018 a Diciembre 2021
  3. Foeniculum vulgare (hinojo): alternativa terapéutica femenina
  4. Adenoviral gene therapy for bladder cancer.
  5. Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells.
  6. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy.
  7. [A study of the clinical curative effect of nucleos(t)ide analogues treated to pegylated interferon-α add-on therapy in patients with chronic hepatitis B].
  8. [Precise immunological classification guidance for early initiation of antiviral therapy in patients with chronic HBV infection].
  9. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
  10. Cannabis medicinal: puntos críticos para su uso clínico